This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dhillon, N. Articles by Kurzrock, R. Search for Related Content PubMed PubMed Citation Articles by Dhillon, N. Articles by Kurzrock, R.

Phase II Trial of Curcumin in Patients with Advanced Pancreatic Cancer

Authors’ Affiliations: ¹ Phase I Program, Department of Investigational Cancer Therapeutics, ² Department of Experimental Therapeutics, ³ Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, and ⁴ Department of Diagnostic Radiology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas and ⁵ Sabinsa Corporation, Piscataway, New Jersey

Requests for reprints: Razelle Kurzrock, Phase I Program, The University of Texas M. D. Anderson Cancer Center, Unit 455, Houston, TX 77030. Phone: 713-794-1226; E-mail: rkurzroc{at}mdanderson.org.

Purpose: Pancreatic cancer is almost always lethal, and the only U.S. Food and Drug Administration–approved therapies for it, gemcitabine and erlotinib, produce objective responses in <10% of patients. We evaluated the clinical biological effects of curcumin (diferuloylmethane), a plant-derived dietary ingredient with potent nuclear factor-B (NF-B) and tumor inhibitory properties, against advanced pancreatic cancer.

Experimental Design: Patients received 8 g curcumin by mouth daily until disease progression, with restaging every 2 months. Serum cytokine levels for interleukin (IL)-6, IL-8, IL-10, and IL-1 receptor antagonists and peripheral blood mononuclear cell expression of NF-B and cyclooxygenase-2 were monitored.

Results: Twenty-five patients were enrolled, with 21 evaluable for response. Circulating curcumin was detectable as drug in glucuronide and sulfate conjugate forms, albeit at low steady-state levels, suggesting poor oral bioavailability. Two patients showed clinical biological activity. One had ongoing stable disease for >18 months; interestingly, one additional patient had a brief, but marked, tumor regression (73%) accompanied by significant increases (4- to 35-fold) in serum cytokine levels (IL-6, IL-8, IL-10, and IL-1 receptor antagonists). No toxicities were observed. Curcumin down-regulated expression of NF-B, cyclooxygenase-2, and phosphorylated signal transducer and activator of transcription 3 in peripheral blood mononuclear cells from patients (most of whom had baseline levels considerably higher than those found in healthy volunteers). Whereas there was considerable interpatient variation in plasma curcumin levels, drug levels peaked at 22 to 41 ng/mL and remained relatively constant over the first 4 weeks.

Conclusions: Oral curcumin is well tolerated and, despite its limited absorption, has biological activity in some patients with pancreatic cancer.

This article has been cited by other articles:

				C. M. MACH, L. MATHEW, S. A. MOSLEY, R. KURZROCK, and J. A. SMITH Determination of Minimum Effective Dose and Optimal Dosing Schedule for Liposomal Curcumin in a Xenograft Human Pancreatic Cancer Model Anticancer Res, June 1, 2009; 29(6): 1895 - 1899. [Abstract] [Full Text] [PDF]

				B. Sung, A. B. Kunnumakkara, G. Sethi, P. Anand, S. Guha, and B. B. Aggarwal Curcumin circumvents chemoresistance in vitro and potentiates the effect of thalidomide and bortezomib against human multiple myeloma in nude mice model Mol. Cancer Ther., April 1, 2009; 8(4): 959 - 970. [Abstract] [Full Text] [PDF]

				M. Suzuki, T. Betsuyaku, Y. Ito, K. Nagai, N. Odajima, C. Moriyama, Y. Nasuhara, and M. Nishimura Curcumin attenuates elastase- and cigarette smoke-induced pulmonary emphysema in mice Am J Physiol Lung Cell Mol Physiol, April 1, 2009; 296(4): L614 - L623. [Abstract] [Full Text] [PDF]

				L. S. Angelo and R. Kurzrock Turmeric and Green Tea: A Recipe for the Treatment of B-Chronic Lymphocytic Leukemia Clin. Cancer Res., February 15, 2009; 15(4): 1123 - 1125. [Abstract] [Full Text] [PDF]

				B. B. Aggarwal, R.V. Vijayalekshmi, and B. Sung Targeting Inflammatory Pathways for Prevention and Therapy of Cancer: Short-Term Friend, Long-Term Foe Clin. Cancer Res., January 15, 2009; 15(2): 425 - 430. [Abstract] [Full Text] [PDF]

				B. T. Kurien and R. H. Scofield Heat-Solubilized Curcumin Should Be Considered in Clinical Trials for Increasing Bioavailability Clin. Cancer Res., January 15, 2009; 15(2): 747 - 747. [Full Text] [PDF]

				R. Kurzrock and N. Dhillon Clin. Cancer Res., January 15, 2009; 15(2): 747 - 747. [Full Text] [PDF]